Short interest in Pulmatrix Inc (NASDAQ:PULM) decreased during the last reporting period, falling from 7.29K to 3.61K. This put 0.1% of the company's publicly available shares short. Short interest in ...

Robert Clarke is taking over as CEO of Pulmatrix, a clinical stage biotech firm that develops inhaled therapeutics. Clarke was formerly the company’s chief science officer. Pulmatrix is based in ...

A look at the shareholders of Pulmatrix Inc (NASDAQ:PULM) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual to see insiders ...

This week we saw the Pulmatrix, Inc. (NASDAQ:PULM) share price climb by 26%. But will that heal all the wounds inflicted over 5 years of declines? Unlikely. Like a ship taking on water, the share ...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares ...

PULM is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of PULM shares has decreased $0.02 since the market last closed. This is a 1.15 ...

Company Positioned to Demonstrate Value of iCALM(TM) Platform for A New Class of Inhaled Therapeutics for Serious and Chronic Respiratory Diseases Lexington, MA, August 15, 2011 -- Pulmatrix, a ...

Combined company to operate as Eos SENOLYTIX, a first-in-class anti-aging biotechnology company $19 million financings to advance lead clinical candidate PTC-2105 for sarcopenia and age-related ...

"We are very excited to have three iSPERSE enabled programs with potential to address significant unmet need in lung cancer, allergic bronchopulmonary aspergillosis, and acute migraine," said Ted Raad ...

Pulmatrix, Inc., (NASDAQ: PULM), previously known as Ruthigen, Inc., today announced the completion of its previously announced merger, effective June 15, 2015, and the closing of a private placement ...

Ruthigen said today it will merge with Pulmatrix, creating a combined drug developer that will focus on commercializing the latter’s inhaled therapeutic products. Pulmatrix would become a wholly-owned ...